- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Woburn Today
By the People, for the People
Azurity Pharmaceuticals Launches ARYNTA for ADHD Treatment
New lisdexamfetamine dimesylate medication now available for patients.
Apr. 6, 2026 at 6:30pm
Got story updates? Submit your updates here. ›
The launch of a new ADHD medication offers patients and doctors an additional treatment option for managing this common neurodevelopmental disorder.Woburn TodayAzurity Pharmaceuticals, a pharmaceutical company based in Woburn, Massachusetts, has announced the availability of their new medication ARYNTA, which contains the active ingredient lisdexamfetamine dimesylate for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Why it matters
The launch of ARYNTA provides a new treatment option for patients with ADHD, a common neurodevelopmental disorder that can significantly impact a person's ability to focus, control impulsive behaviors, and manage everyday tasks. As the pharmaceutical landscape continues to evolve, the availability of new branded medications can offer healthcare providers more choices when determining the best course of treatment for their patients.
The details
ARYNTA is a central nervous system (CNS) stimulant medication that works by increasing the availability of certain neurotransmitters in the brain, helping to improve focus and concentration. It is approved for the treatment of ADHD in both children and adults.
- Azurity Pharmaceuticals announced the availability of ARYNTA on April 6, 2026.
The players
Azurity Pharmaceuticals, Inc.
A pharmaceutical company based in Woburn, Massachusetts that specializes in developing and commercializing innovative medications.
ARYNTA
A new medication containing the active ingredient lisdexamfetamine dimesylate, approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The takeaway
The launch of ARYNTA provides a new treatment option for patients with ADHD, offering healthcare providers more choices when determining the best course of action for their patients.
